Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 35, Issue 4, 2001, Pages 283-287

  Takezawa, Y ^a   Nakata, S ^a   Kobayashi, M ^a   Kosaku, N ^a   Fukabori, Y ^a   Yamanaka, H ^a  

^a Isesaki Municipal Hospital   (Japan)

Author keywords

Adrenal androgen; Diethylstilbestrol diphosphate; Hormone refractory prostate cancer

Indexed keywords

FOSFESTROL; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SIDE EFFECT; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DIETHYLSTILBESTROL; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0034801596     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655901750425855     Document Type: Article

References (26)

1. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter trial of 6630 men
2. Random systemic versus directed ultrasound guided transrectal core biopsy of the prostate
3. Stage at presentation and survival of white and black patients with prostate carcinoma
4. Study on prostate cancer 1. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate
5. Hormonal therapy in the management of prostate cancer: From Huggins to the present
6. Challenges in the management of prostate cancer
7. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma
8. Treatment of progressive metastatic prostate cancer
9. Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment advanced prostatic carcinoma: A controlled study
10. High-dose intravenous estrogen therapy in advanced prostatic carcinoma
11. A phase II study of high-dose estrogen (diethylstilbestrol diphosphate) in prostate cancer
12. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate
13. Induction of apotosis by diethylstilbestrol in hormone-insensitive prostate cancer cells
14. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly
15. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
16. The clinical usefulness of serum prostrate specific antigen after hormonal therapy of metastatic prostate cancer
17. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
18. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A randomized trial with palliative end points
19. A phase II trial if oral diethylstildiphosphate as a second-line hormonal agent in advanced prostate cancer
20. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agents
21. Orhidectomy or oestrogen treatment in prostatic cancer: Effects on serum levels of adrenal androgens and related steroids
22. Complete androgen blockade for the treatment of prostate cancer
23. Intracrinology
24. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
25. Androgen receptor gene amplification: A possible mechanism for androgen deprivation therapy failure in prostate cancer
26. 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells